- $273.44m
- -$144.49m
- $135.16m
Annual cashflow statement for Prothena, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -111 | 67 | -117 | -147 | -122 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 27.5 | 30.3 | 37.3 | 48.4 | 48.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.48 | -10.4 | -18.8 | -20.5 | -67.9 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -80.4 | 92.6 | -109 | -134 | -150 |
| Capital Expenditures | -0.196 | -0.575 | -0.464 | -2.81 | -0.298 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0 | — | 0.037 | 0 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.196 | -0.575 | -0.464 | -2.77 | -0.298 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.215 | 190 | 241 | 45.1 | 1.55 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -80.3 | 282 | 132 | -91.6 | -149 |